Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

v3.23.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Treasury Stock, Common [Member]
Total
Beginning balance, value at Dec. 31, 2020 $ 2,774 $ 8,771 $ 194,133,511 $ (176,902,086) $ 253,734 $ (5,281,180) $ 12,215,524
Beginning balance, shares at Dec. 31, 2020 2,774,394 8,772,198          
Issuance of common stock and warrants, net of issuance costs $ 950 11,449,916 11,450,866
Issuance of common stock and warrants, net of issuance costs, shares   950,000          
Exercise of pre-funded warrants $ 3,679 3,679
Exercise of pre-funded warrants, shares   3,679,630          
Exercise of purchase warrants $ 6 (6)
Exercise of purchase warrants, shares   5,988          
Share-based expense 410,437 410,437
Issuance of common stock to vendor $ 7 (7)
Issuance of common stock to vendor, shares   7,153          
Issuance of common stock in connection with warrant buyout $ 52 (41,122) (41,070)
Issuance of common stock in connection with warrant buyout, shares   51,634          
Net loss (5,645,179) (5,645,179)
Ending balance, value at Dec. 31, 2021 $ 2,774 $ 13,465 205,952,729 (182,547,265) 253,734 (5,281,180) 18,394,257
Ending balance, shares at Dec. 31, 2021 2,774,394 13,466,603          
Issuance of common stock in connection with purchase of in-process research and development $ 1,725 1,292,025 1,293,750
Issuance of common stock in connection with purchase of in-process research and development, shares   1,725,000          
Exercise of purchase warrants $ 2 (2)
Exercise of purchase warrants, shares   1,984          
Share-based expense 511,480 511,480
Net loss (6,552,353) (6,552,353)
Ending balance, value at Dec. 31, 2022 $ 2,774 $ 15,192 $ 207,756,232 $ (189,099,618) $ 253,734 $ (5,281,180) $ 13,647,134
Ending balance, shares at Dec. 31, 2022 2,774,394 15,193,587